Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...
New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures ...
Lacosamide 10mg/mL; strawberry-flavored; contains phenylalanine 0.32mg/20mL. See full labeling. Tabs: swallow whole. Oral soln: use calibrated measuring device. Injection: can give without diluting, ...
Atlanta – March 11, 2010 – press release – UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in ...
ATLANTA – May 26, 2009 – press release, regulated information – UCB today announced that Vimpat® (lacosamide) C-V , a new antiepileptic drug (AED) is available in the U.S. as an add-on therapy for the ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to lacosamide or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results